OHSU

IRB #

IRB00008296

Title

Phase I Infusional Cyclophosphamide and Pulse Dexamethasone With Rapamycin and Hydroxychloroquine in Patients With Relapsed or Refractory Myeloma

Principal Investigator

Emma Scott

Study Purpose

This protocol will enroll subjects who have multiple myeloma that has returned after treatment or has stopped responding to treatment. The purpose of this study is to test the safety of rapamycin and hydroxychloroquine (study drugs) at different dose levels. We believe that the combination of standard chemotherapy with the study drugs may improve the response outcome compared to standard chemotherapy alone.

Medical Condition(s)

Relapsed or Refractory Multiple Myeloma

Eligibility Criteria

Subjects should have relapsed/ refractory multiple myeloma.
Subjects should be 18 years or older.
Subjects should not have an uncontrolled intercurrent illness.

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

Up to 24 months

Minors Included

No

Contact

Sponsor

N/A

Recruitment End

12/01/2025

Compensation Provided

No


Go Back